APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Liposomal and Lipid-based Nanoparticle Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Liposomal and Lipid-based Nanoparticle Drug Market Outlook and Growth Opportunities 2026

Report ID 17400787042 January 2026205 pages

Choose your research edition.

Industry ResearchLiposomal and Lipid-based Nanoparticle Drug Industry Research Report 2026141 pages · $2,950 USDIndustry Growth & TrendsGlobal Liposomal and Lipid-based Nanoparticle Drug Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Liposomal and Lipid-based Nanoparticle Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Liposomal and Lipid-based Nanoparticle Drug Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Liposomal and Lipid-based Nanoparticle Drug Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Liposomal and Lipid-based Nanoparticle Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Liposomal and Lipid-based Nanoparticle Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Liposomal and Lipid-based Nanoparticle Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Liposomal and Lipid-based Nanoparticle Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Liposomal and Lipid-based Nanoparticle Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Liposomal and Lipid-based Nanoparticle Drug market include Acrotech Biopharma, Alnylam, Bausch Health, Chiesi Farmaceutici, CSPC, Fudan-Zhangjiang, Gilead Sciences, Ipsen and Jazz, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Liposomal and Lipid-based Nanoparticle Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Liposomal and Lipid-based Nanoparticle Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Liposomal and Lipid-based Nanoparticle Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Liposomal and Lipid-based Nanoparticle Drug market.

Liposomal and Lipid-based Nanoparticle Drug Segment by Company

Acrotech Biopharma

Alnylam

Bausch Health

Chiesi Farmaceutici

CSPC

Fudan-Zhangjiang

Gilead Sciences

Ipsen

Jazz

Kinyond

Leadiant Biosciences

Luye Pharma

Pacira

Sayre Therapeutics

TTY Biopharma

Zydus Cadila

Johnson & Johnson

Sun Pharmaceutical

Teva

Takeda

Liposomal and Lipid-based Nanoparticle Drug Segment by Type

Liposomes Drugs

Lipid Nanoparticle Drugs

Liposomal and Lipid-based Nanoparticle Drug Segment by Application

Hospital

Retail Pharmacy

Other

Liposomal and Lipid-based Nanoparticle Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Liposomal and Lipid-based Nanoparticle Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Liposomal and Lipid-based Nanoparticle Drug key companies, revenue, market share, and recent developments.

3. To split the Liposomal and Lipid-based Nanoparticle Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Liposomal and Lipid-based Nanoparticle Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Liposomal and Lipid-based Nanoparticle Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Liposomal and Lipid-based Nanoparticle Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liposomal and Lipid-based Nanoparticle Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Liposomal and Lipid-based Nanoparticle Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liposomal and Lipid-based Nanoparticle Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Liposomal and Lipid-based Nanoparticle Drug industry.

Chapter 3: Detailed analysis of Liposomal and Lipid-based Nanoparticle Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Liposomal and Lipid-based Nanoparticle Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Liposomal and Lipid-based Nanoparticle Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Liposomal and Lipid-based Nanoparticle Drug Industry Trends Table 2. Liposomal and Lipid-based Nanoparticle Drug Industry Drivers Table 3. Liposomal and Lipid-based Nanoparticle Drug Industry Opportunities and Challenges Table 4. Liposomal and Lipid-based Nanoparticle Drug Industry Restraints Table 5. Global Liposomal and Lipid-based Nanoparticle Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Liposomal and Lipid-based Nanoparticle Drug Revenue Share by Company (2021-2026) Table 7. Global Liposomal and Lipid-based Nanoparticle Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Liposomal and Lipid-based Nanoparticle Drug Key Company Manufacturing Base & Headquarters Table 9. Global Liposomal and Lipid-based Nanoparticle Drug Company, Product Type & Application Table 10. Global Liposomal and Lipid-based Nanoparticle Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Liposomal and Lipid-based Nanoparticle Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Liposomes Drugs Table 15. Significant Companies of Lipid Nanoparticle Drugs Table 16. Global Liposomal and Lipid-based Nanoparticle Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Liposomal and Lipid-based Nanoparticle Drug Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Liposomal and Lipid-based Nanoparticle Drug Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type (2021-2026) Table 20. Global Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Retail Pharmacy Table 23. Significant Companies of Other Table 24. Global Liposomal and Lipid-based Nanoparticle Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Liposomal and Lipid-based Nanoparticle Drug Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Liposomal and Lipid-based Nanoparticle Drug Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application (2021-2026) Table 28. Global Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application (2027-2032) Table 29. Global Liposomal and Lipid-based Nanoparticle Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Liposomal and Lipid-based Nanoparticle Drug Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Region (2021-2026) Table 32. Global Liposomal and Lipid-based Nanoparticle Drug Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Region (2027-2032) Table 34. Global Liposomal and Lipid-based Nanoparticle Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Liposomal and Lipid-based Nanoparticle Drug Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Liposomal and Lipid-based Nanoparticle Drug Sales Value Market Share by Country (2021-2026) Table 37. Global Liposomal and Lipid-based Nanoparticle Drug Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Liposomal and Lipid-based Nanoparticle Drug Sales Value Market Share by Country (2027-2032) Table 39. Acrotech Biopharma Company Information Table 40. Acrotech Biopharma Business Overview Table 41. Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 43. Acrotech Biopharma Recent Development Table 44. Alnylam Company Information Table 45. Alnylam Business Overview Table 46. Alnylam Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Alnylam Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 48. Alnylam Recent Development Table 49. Bausch Health Company Information Table 50. Bausch Health Business Overview Table 51. Bausch Health Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Bausch Health Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 53. Bausch Health Recent Development Table 54. Chiesi Farmaceutici Company Information Table 55. Chiesi Farmaceutici Business Overview Table 56. Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 58. Chiesi Farmaceutici Recent Development Table 59. CSPC Company Information Table 60. CSPC Business Overview Table 61. CSPC Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. CSPC Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 63. CSPC Recent Development Table 64. Fudan-Zhangjiang Company Information Table 65. Fudan-Zhangjiang Business Overview Table 66. Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 68. Fudan-Zhangjiang Recent Development Table 69. Gilead Sciences Company Information Table 70. Gilead Sciences Business Overview Table 71. Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 73. Gilead Sciences Recent Development Table 74. Ipsen Company Information Table 75. Ipsen Business Overview Table 76. Ipsen Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Ipsen Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 78. Ipsen Recent Development Table 79. Jazz Company Information Table 80. Jazz Business Overview Table 81. Jazz Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Jazz Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 83. Jazz Recent Development Table 84. Kinyond Company Information Table 85. Kinyond Business Overview Table 86. Kinyond Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Kinyond Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 88. Kinyond Recent Development Table 89. Leadiant Biosciences Company Information Table 90. Leadiant Biosciences Business Overview Table 91. Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 93. Leadiant Biosciences Recent Development Table 94. Luye Pharma Company Information Table 95. Luye Pharma Business Overview Table 96. Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 98. Luye Pharma Recent Development Table 99. Pacira Company Information Table 100. Pacira Business Overview Table 101. Pacira Liposomal and Lipid-based Nanoparticle Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Pacira Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 103. Pacira Recent Development Table 104. Sayre Therapeutics Company Information Table 105. Sayre Therapeutics Business Overview Table 106. Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 108. Sayre Therapeutics Recent Development Table 109. TTY Biopharma Company Information Table 110. TTY Biopharma Business Overview Table 111. TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 113. TTY Biopharma Recent Development Table 114. Zydus Cadila Company Information Table 115. Zydus Cadila Business Overview Table 116. Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 118. Zydus Cadila Recent Development Table 119. Johnson & Johnson Company Information Table 120. Johnson & Johnson Business Overview Table 121. Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 123. Johnson & Johnson Recent Development Table 124. Sun Pharmaceutical Company Information Table 125. Sun Pharmaceutical Business Overview Table 126. Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 128. Sun Pharmaceutical Recent Development Table 129. Teva Company Information Table 130. Teva Business Overview Table 131. Teva Liposomal and Lipid-based Nanoparticle Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Teva Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 133. Teva Recent Development Table 134. Takeda Company Information Table 135. Takeda Business Overview Table 136. Takeda Liposomal and Lipid-based Nanoparticle Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Takeda Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 138. Takeda Recent Development Table 139. Research Programs/Design for This Report Table 140. Authors List of This Report Table 141. Secondary Sources Table 142. Primary Sources List of Figures Figure 1. Liposomal and Lipid-based Nanoparticle Drug Product Image Figure 2. Global Liposomal and Lipid-based Nanoparticle Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Liposomal and Lipid-based Nanoparticle Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Liposomal and Lipid-based Nanoparticle Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Liposomes Drugs Image Figure 8. Lipid Nanoparticle Drugs Image Figure 9. Global Liposomal and Lipid-based Nanoparticle Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Liposomal and Lipid-based Nanoparticle Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Retail Pharmacy Image Figure 14. Other Image Figure 15. Global Liposomal and Lipid-based Nanoparticle Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Liposomal and Lipid-based Nanoparticle Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application (2021-2032) Figure 18. Global Liposomal and Lipid-based Nanoparticle Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Liposomal and Lipid-based Nanoparticle Drug Sales Value (2021-2032) & (US$ Million) Figure 21. North America Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Liposomal and Lipid-based Nanoparticle Drug Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Liposomal and Lipid-based Nanoparticle Drug Sales Value (2021-2032) & (US$ Million) Figure 27. South America Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Liposomes Drugs
  • Lipid Nanoparticle Drugs
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Acrotech Biopharma
  • Alnylam
  • Bausch Health
  • Chiesi Farmaceutici
  • CSPC
  • Fudan-Zhangjiang
  • Gilead Sciences
  • Ipsen
  • Jazz
  • Kinyond
  • Leadiant Biosciences
  • Luye Pharma
  • Pacira
  • Sayre Therapeutics
  • TTY Biopharma
  • Zydus Cadila
  • Johnson & Johnson
  • Sun Pharmaceutical
  • Teva
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Liposomal and Lipid-based Nanoparticle Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Liposomal and Lipid-based Nanoparticle Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Liposomal and Lipid-based Nanoparticle Drug Market Dynamics
  1. 2.1 Liposomal and Lipid-based Nanoparticle Drug Industry Trends
  2. 2.2 Liposomal and Lipid-based Nanoparticle Drug Industry Drivers
  3. 2.3 Liposomal and Lipid-based Nanoparticle Drug Industry Opportunities and Challenges
  4. 2.4 Liposomal and Lipid-based Nanoparticle Drug Industry Restraints
3 Liposomal and Lipid-based Nanoparticle Drug Market by Company
  1. 3.1 Global Liposomal and Lipid-based Nanoparticle Drug Company Revenue Ranking in 2025
  2. 3.2 Global Liposomal and Lipid-based Nanoparticle Drug Revenue by Company (2021-2026)
  3. 3.3 Global Liposomal and Lipid-based Nanoparticle Drug Company Ranking (2024-2026)
  4. 3.4 Global Liposomal and Lipid-based Nanoparticle Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Liposomal and Lipid-based Nanoparticle Drug Company Product Type and Application
  6. 3.6 Global Liposomal and Lipid-based Nanoparticle Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Liposomal and Lipid-based Nanoparticle Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Liposomal and Lipid-based Nanoparticle Drug Market by Type
  1. 4.1 Liposomal and Lipid-based Nanoparticle Drug Type Introduction
  2. 4.1.1 Liposomes Drugs
  3. 4.1.2 Lipid Nanoparticle Drugs
  4. 4.2 Global Liposomal and Lipid-based Nanoparticle Drug Sales Value by Type
  5. 4.2.1 Global Liposomal and Lipid-based Nanoparticle Drug Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Liposomal and Lipid-based Nanoparticle Drug Sales Value by Type (2021-2032)
  7. 4.2.3 Global Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type (2021-2032)
5 Liposomal and Lipid-based Nanoparticle Drug Market by Application
  1. 5.1 Liposomal and Lipid-based Nanoparticle Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Liposomal and Lipid-based Nanoparticle Drug Sales Value by Application
  6. 5.2.1 Global Liposomal and Lipid-based Nanoparticle Drug Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Liposomal and Lipid-based Nanoparticle Drug Sales Value by Application (2021-2032)
  8. 5.2.3 Global Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application (2021-2032)
6 Liposomal and Lipid-based Nanoparticle Drug Regional Value Analysis
  1. 6.1 Global Liposomal and Lipid-based Nanoparticle Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Liposomal and Lipid-based Nanoparticle Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Liposomal and Lipid-based Nanoparticle Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Liposomal and Lipid-based Nanoparticle Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Liposomal and Lipid-based Nanoparticle Drug Sales Value (2021-2032)
  7. 6.3.2 North America Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Liposomal and Lipid-based Nanoparticle Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Liposomal and Lipid-based Nanoparticle Drug Sales Value (2021-2032)
  16. 6.6.2 South America Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Country, 2025 VS 2032
7 Liposomal and Lipid-based Nanoparticle Drug Country-level Value Analysis
  1. 7.1 Global Liposomal and Lipid-based Nanoparticle Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Liposomal and Lipid-based Nanoparticle Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Liposomal and Lipid-based Nanoparticle Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Liposomal and Lipid-based Nanoparticle Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Liposomal and Lipid-based Nanoparticle Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Liposomal and Lipid-based Nanoparticle Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Acrotech Biopharma
  2. 8.1.1 Acrotech Biopharma Company Information
  3. 8.1.2 Acrotech Biopharma Business Overview
  4. 8.1.3 Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  6. 8.1.5 Acrotech Biopharma Recent Developments
  7. 8.2 Alnylam
  8. 8.2.1 Alnylam Company Information
  9. 8.2.2 Alnylam Business Overview
  10. 8.2.3 Alnylam Liposomal and Lipid-based Nanoparticle Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Alnylam Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  12. 8.2.5 Alnylam Recent Developments
  13. 8.3 Bausch Health
  14. 8.3.1 Bausch Health Company Information
  15. 8.3.2 Bausch Health Business Overview
  16. 8.3.3 Bausch Health Liposomal and Lipid-based Nanoparticle Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bausch Health Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  18. 8.3.5 Bausch Health Recent Developments
  19. 8.4 Chiesi Farmaceutici
  20. 8.4.1 Chiesi Farmaceutici Company Information
  21. 8.4.2 Chiesi Farmaceutici Business Overview
  22. 8.4.3 Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  24. 8.4.5 Chiesi Farmaceutici Recent Developments
  25. 8.5 CSPC
  26. 8.5.1 CSPC Company Information
  27. 8.5.2 CSPC Business Overview
  28. 8.5.3 CSPC Liposomal and Lipid-based Nanoparticle Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 CSPC Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  30. 8.5.5 CSPC Recent Developments
  31. 8.6 Fudan-Zhangjiang
  32. 8.6.1 Fudan-Zhangjiang Company Information
  33. 8.6.2 Fudan-Zhangjiang Business Overview
  34. 8.6.3 Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  36. 8.6.5 Fudan-Zhangjiang Recent Developments
  37. 8.7 Gilead Sciences
  38. 8.7.1 Gilead Sciences Company Information
  39. 8.7.2 Gilead Sciences Business Overview
  40. 8.7.3 Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  42. 8.7.5 Gilead Sciences Recent Developments
  43. 8.8 Ipsen
  44. 8.8.1 Ipsen Company Information
  45. 8.8.2 Ipsen Business Overview
  46. 8.8.3 Ipsen Liposomal and Lipid-based Nanoparticle Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Ipsen Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  48. 8.8.5 Ipsen Recent Developments
  49. 8.9 Jazz
  50. 8.9.1 Jazz Company Information
  51. 8.9.2 Jazz Business Overview
  52. 8.9.3 Jazz Liposomal and Lipid-based Nanoparticle Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Jazz Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  54. 8.9.5 Jazz Recent Developments
  55. 8.10 Kinyond
  56. 8.10.1 Kinyond Company Information
  57. 8.10.2 Kinyond Business Overview
  58. 8.10.3 Kinyond Liposomal and Lipid-based Nanoparticle Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Kinyond Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  60. 8.10.5 Kinyond Recent Developments
  61. 8.11 Leadiant Biosciences
  62. 8.11.1 Leadiant Biosciences Company Information
  63. 8.11.2 Leadiant Biosciences Business Overview
  64. 8.11.3 Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  66. 8.11.5 Leadiant Biosciences Recent Developments
  67. 8.12 Luye Pharma
  68. 8.12.1 Luye Pharma Company Information
  69. 8.12.2 Luye Pharma Business Overview
  70. 8.12.3 Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  72. 8.12.5 Luye Pharma Recent Developments
  73. 8.13 Pacira
  74. 8.13.1 Pacira Company Information
  75. 8.13.2 Pacira Business Overview
  76. 8.13.3 Pacira Liposomal and Lipid-based Nanoparticle Drug Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Pacira Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  78. 8.13.5 Pacira Recent Developments
  79. 8.14 Sayre Therapeutics
  80. 8.14.1 Sayre Therapeutics Company Information
  81. 8.14.2 Sayre Therapeutics Business Overview
  82. 8.14.3 Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  84. 8.14.5 Sayre Therapeutics Recent Developments
  85. 8.15 TTY Biopharma
  86. 8.15.1 TTY Biopharma Company Information
  87. 8.15.2 TTY Biopharma Business Overview
  88. 8.15.3 TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Revenue and Gross Margin (2021-2026)
  89. 8.15.4 TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  90. 8.15.5 TTY Biopharma Recent Developments
  91. 8.16 Zydus Cadila
  92. 8.16.1 Zydus Cadila Company Information
  93. 8.16.2 Zydus Cadila Business Overview
  94. 8.16.3 Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  96. 8.16.5 Zydus Cadila Recent Developments
  97. 8.17 Johnson & Johnson
  98. 8.17.1 Johnson & Johnson Company Information
  99. 8.17.2 Johnson & Johnson Business Overview
  100. 8.17.3 Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  102. 8.17.5 Johnson & Johnson Recent Developments
  103. 8.18 Sun Pharmaceutical
  104. 8.18.1 Sun Pharmaceutical Company Information
  105. 8.18.2 Sun Pharmaceutical Business Overview
  106. 8.18.3 Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  108. 8.18.5 Sun Pharmaceutical Recent Developments
  109. 8.19 Teva
  110. 8.19.1 Teva Company Information
  111. 8.19.2 Teva Business Overview
  112. 8.19.3 Teva Liposomal and Lipid-based Nanoparticle Drug Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Teva Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  114. 8.19.5 Teva Recent Developments
  115. 8.20 Takeda
  116. 8.20.1 Takeda Company Information
  117. 8.20.2 Takeda Business Overview
  118. 8.20.3 Takeda Liposomal and Lipid-based Nanoparticle Drug Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Takeda Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  120. 8.20.5 Takeda Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst